Schober, Kilian http://orcid.org/0000-0001-9323-9472
Voit, Florian http://orcid.org/0000-0002-6957-6628
Grassmann, Simon
Müller, Thomas R. http://orcid.org/0000-0001-5331-5522
Eggert, Joel
Jarosch, Sebastian
Weißbrich, Bianca
Hoffmann, Patrick
Borkner, Lisa
Nio, Enzo
Fanchi, Lorenzo
Clouser, Christopher R.
Radhakrishnan, Aditya
Mihatsch, Lorenz
Lückemeier, Philipp
Leube, Justin
Dössinger, Georg
Klein, Ludger
Neuenhahn, Michael
Oduro, Jennifer D.
Cicin-Sain, Luka
Buchholz, Veit R. http://orcid.org/0000-0003-0441-3913
Busch, Dirk H. http://orcid.org/0000-0001-8713-093X
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB 1321/TP17, SFB 1054/B09, SFB 1371/TP04, FOR2830/TP5, SFB 1054/B09)
Article History
Received: 29 September 2019
Accepted: 5 February 2020
First Online: 16 March 2020
Competing interests
: D.H.B. is co-founder of STAGE Cell Therapeutics GmbH (now Juno Therapeutics/Celgene) and T Cell Factory B.V. (now Kite/Gilead). D.H.B. has a consulting contract with and receives sponsored research support from Juno Therapeutics/Celgene. C.R.C. and A.R. are employees of Juno Therapeutics/Celgene. E.N. and L.F. are employees of ENPICOM B.V. The other authors declare no competing interests.